AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22673023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 759
Study 22673023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 759
Study 19322618 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating-platform TKA
Number of subjects: 54
Study 19322618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-platform TKA
Number of subjects: 54
Study 19322618 — intervention group
Group type: COMPARATOR
Intervention: Nonoperated contralateral side
Number of subjects: 54
Study 18834503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk in numerical format (natural frequencies, i.e. X out of 100)
Number of subjects: 0
Study 18834503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk in both numerical format and graphical format (population figures)
Number of subjects: 0
Study 18834503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk and age-related risk in numerical format
Number of subjects: 0
Study 18834503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk and age-related risk in both numerical format and graphical format
Number of subjects: 0
Study 18834503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk in percentages
Number of subjects: 0
Study 18834503 — intervention group
Group type: COMPARATOR
Intervention: Control condition (usual care)
Number of subjects: 0
Study 16491675 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiogenic condition
Number of subjects: 61
Study 16491675 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study 12957458 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation of the internal mammary and medial supraclavicular lymph nodes
Number of subjects: 111
Study 12957458 — intervention group
Group type: COMPARATOR
Intervention: No irradiation of the internal mammary and medial supraclavicular lymph nodes
Number of subjects: 111
Study 11004260 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune recovery uveitis patients undergoing highly active antiretroviral therapy
Number of subjects: 21
Study 11004260 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior segment complications
Number of subjects: 21
Study 11004260 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior segment complications
Number of subjects: 21
Study 11004260 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 21
Study 8862992 — intervention group
Group type: EXPERIMENTAL
Intervention: Coded postcard intervention
Number of subjects: 1600
Study 8862992 — intervention group
Group type: COMPARATOR
Intervention: Control group (three complete anonymous mailings)
Number of subjects: 1600
Study 1627418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 1 year
Number of subjects: 961
Study 1627418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 1 year
Number of subjects: 961
Study 1627418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 961
Study 1627418 — intervention group
Group type: COMPARATOR
Intervention: Irradiation-induced menopause
Number of subjects: 961
Study 1627418 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 961
Study 6383166 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 100
Study 6383166 — intervention group
Group type: COMPARATOR
Intervention: Double-contrast barium meal
Number of subjects: 100
Study 3676232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with egg supplementation (two whole eggs and two egg yolks daily)
Number of subjects: 17
Study 3676232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet with egg supplementation
Number of subjects: 17
Study 3676232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary regimen of four eggs per day
Number of subjects: 17
Study 3676232 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cholesterol intake
Number of subjects: 17
Study 29861225 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral thoracic PA in slump position (SLUMP group)
Number of subjects: 60
Study 29861225 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior‐to‐anterior (PA) rotatory thoracic passive accessory intervertebral mobilization (PAIVM) (PA group)
Number of subjects: 60
Study 29861225 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (Placebo group)
Number of subjects: 60
Study 28222825 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention (Climate Schools)
Number of subjects: 2190
Study 28222825 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective prevention (Preventure)
Number of subjects: 2190
Study 28222825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prevention (Climate Schools and Preventure; CAP)
Number of subjects: 2190
Study 28222825 — intervention group
Group type: COMPARATOR
Intervention: Health education as usual (control)
Number of subjects: 2190
Study 26036465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored brief intervention (BI)
Number of subjects: 957
Study 26036465 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 957
Study 23930204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) in combination with capecitabine (C) and mitomycin C (M)
Number of subjects: 302
Study 23930204 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (C)
Number of subjects: 302
Study 20199404 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl alcohol lotion 5% (BAL 5%)
Number of subjects: 695
Study 18312045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 18240
Study 18312045 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 18240
Study 16557041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (AA)
Number of subjects: 0
Study 16557041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (AA) + mood stabilizers
Number of subjects: 0
Study 16557041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizers
Number of subjects: 0
Study 16557041 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study 11966338 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 5499
Study 11966338 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5499
Study 9816888 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA-positive sera from systemic vasculitis patients (titre > or = 4:40)
Number of subjects: 191
Study 9816888 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA-negative GN sera
Number of subjects: 191
Study 9816888 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy individuals (negative control group)
Number of subjects: 191
Study 9816888 — intervention group
Group type: COMPARATOR
Intervention: Second negative reference system without serum
Number of subjects: 191
Study 7663809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Maximal Inflations (SMI)
Number of subjects: 228
Study 7663809 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐handed percussions (SSP)
Number of subjects: 228
Study 7663809 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 228
Study 2526933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2526933 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg x 2)
Number of subjects: 9
Study 2526933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (1000 mg, 11 h prior to study)
Number of subjects: 9
Study 71605 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 0
Study 31747786 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident NSAID use
Number of subjects: 17423
Study 31747786 — intervention group
Group type: COMPARATOR
Intervention: NSAID use at baseline
Number of subjects: 17423
Study 29948437 — intervention group
Group type: EXPERIMENTAL
Intervention: Olweus Bully Prevention Program (OBPP)
Number of subjects: 1791
Study 27116023 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid dosing (morphine and oxycodone)
Number of subjects: 44
Study 27116023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity scores
Number of subjects: 44
Study 24618401 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly application of dehydrated human amnion/chorion membrane allograft
Number of subjects: 40
Study 24618401 — intervention group
Group type: COMPARATOR
Intervention: Biweekly application of dehydrated human amnion/chorion membrane allograft
Number of subjects: 40
Study 22324425 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 18
Study 22324425 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 18
Study 21095282 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 1152
Study 21095282 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest uric acid quartile (>10.4 mg/dL)
Number of subjects: 1152
Study 18479800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts
Number of subjects: 0
Study 18479800 — intervention group
Group type: COMPARATOR
Intervention: Composite resin cores without fiber posts (Control)
Number of subjects: 0
Study 16007279 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 15
Study 16007279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14705265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy over five years
Number of subjects: 0
Study 14705265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy with permanent reduction in breast cancer incidence
Number of subjects: 0
Study 14705265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy with further treatment effects preventing new breast cancers for up to 10 years
Number of subjects: 0
Study 14705265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy with delayed breast cancer incidence
Number of subjects: 0
Study 14705265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10638388 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised meal at 1.5 h after baseline
Number of subjects: 12
Study 10638388 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised meal at 5.5 h after baseline
Number of subjects: 12
Study 10638388 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 12
Study 7856426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 9310
Study 7856426 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9310
Study 2203218 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol and 2% or 4% pilocarpine combination eye drops
Number of subjects: 33
Study 2203218 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol alone
Number of subjects: 33
Study 7387807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 49
Study 7387807 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg kg‐1 followed by pancuronium 0.05 mg kg‐1
Number of subjects: 49
Study 7387807 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium before pancuronium
Number of subjects: 49
Study 29981569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid solution
Number of subjects: 528
Study 29981569 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dextrose solution
Number of subjects: 528
Study 29981569 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 528
Study 29981569 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breastmilk
Number of subjects: 528
Study 29981569 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste/smell given before gastric tube feeds
Number of subjects: 528
Study 29981569 — intervention group
Group type: COMPARATOR
Intervention: Taste/smell not given before gastric tube feeds
Number of subjects: 528
Study 26775091 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) infiltration at the rotator cuff defect
Number of subjects: 40
Study 26775091 — intervention group
Group type: COMPARATOR
Intervention: No PRP (control group)
Number of subjects: 40
Study 24653653 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors and lifestyle modification
Number of subjects: 234
Study 24653653 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 234
Study 23158704 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by clinical nurse specialists every fourth month for 2 years (n = 52)
Number of subjects: 102
Study 23158704 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 102
Study 19688297 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib in combination with hydroxyurea (HU)
Number of subjects: 0
Study 19688297 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU) monotherapy
Number of subjects: 0
Study 18625672 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive pattern (RP) defined by reduced FVC and normal FEV1/FVC ratio
Number of subjects: 2396
Study 18625672 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive pattern (RP) defined by reduced FVC and FEV1/FVC ratio of > or = 85%
Number of subjects: 2396
Study 18625672 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe restrictive pattern (RP)
Number of subjects: 2396
Study 18625672 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive pattern (OP)
Number of subjects: 2396
Study 18625672 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) level > 3.0 mg/L
Number of subjects: 2396
Study 15645268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (IVM) - 3 mg i.v. morphine after spinal anesthesia
Number of subjects: 60
Study 15645268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) - 0.3 mg morphine with bupivacaine during spinal anesthesia
Number of subjects: 60
Study 15645268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (IAM) - 3 mg intra-articular morphine diluted in 10 ml saline before surgery
Number of subjects: 60
Study 15645268 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - no additional drugs
Number of subjects: 60
Study 11788624 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg mifepristone daily for 120 days
Number of subjects: 98
Study 11788624 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone daily for 120 days
Number of subjects: 98
Study 11788624 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg mifepristone daily for 120 days (Shanghai)
Number of subjects: 98
Study 11788624 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone daily for 120 days (Shanghai)
Number of subjects: 98
Study 11788624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of mifepristone
Number of subjects: 98
Study 11788624 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness measurement
Number of subjects: 98
Study 11788624 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Number of subjects: 98
Study 10744888 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt sweetened with 3.75% sucrose
Number of subjects: 0
Study 10744888 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt sweetened with 7.5% sucrose
Number of subjects: 0
Study 10744888 — intervention group
Group type: COMPARATOR
Intervention: Filter paper method
Number of subjects: 0
Study 8692549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ondansetron and dexamethasone
Number of subjects: 0
Study 8692549 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone
Number of subjects: 0
Study 8692549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 1678236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone 17‐valerate cream
Number of subjects: 0
Study 1678236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% prednicarbate cream
Number of subjects: 0
Study 1678236 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of 0.25% prednicarbate cream
Number of subjects: 0
Study 6124991 — intervention group
Group type: EXPERIMENTAL
Intervention: TEM 15 mg
Number of subjects: 8
Study 6124991 — intervention group
Group type: EXPERIMENTAL
Intervention: TEM 30 mg
Number of subjects: 8
Study 6124991 — intervention group
Group type: EXPERIMENTAL
Intervention: MPD + TEM 15 mg
Number of subjects: 8
Study 6124991 — intervention group
Group type: EXPERIMENTAL
Intervention: MPD + TEM 30 mg
Number of subjects: 8
Study 6124991 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + TEM 15 mg
Number of subjects: 8
Study 6124991 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + TEM 30 mg
Number of subjects: 8
Study 6124991 — intervention group
Group type: COMPARATOR
Intervention: CAF (150 mg)
Number of subjects: 8
Study 6124991 — intervention group
Group type: COMPARATOR
Intervention: MPD (10 mg)
Number of subjects: 8
Study 31269599 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (80 kV, 350 mgI/kg, ASIR-V from 10% to 100%)
Number of subjects: 80
Study 29578192 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA alone
Number of subjects: 50
Study 29578192 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA combined with alcohol
Number of subjects: 50
Study 27445325 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 match
Number of subjects: 132
Study 27445325 — intervention group
Group type: COMPARATOR
Intervention: No match
Number of subjects: 132
Study 24517167 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group conferencing (FG-c)
Number of subjects: 0
Study 24517167 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study 22978729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotline consult
Number of subjects: 243
Study 22978729 — intervention group
Group type: COMPARATOR
Intervention: No hotline consult
Number of subjects: 243
Study 20078608 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant 300 mg
Number of subjects: 12
Study 20078608 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant 800 mg
Number of subjects: 12
Study 20078608 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 20078608 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant
Number of subjects: 12
Study 17587399 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day (maximum 200 mg/day) of oral diazoxide
Number of subjects: 35
Study 17587399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 16258098 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus G-CSF (ciprofloxacin and roxithromycin with G-CSF on days 4 to 13)
Number of subjects: 175
Study 16258098 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (ciprofloxacin and roxithromycin)
Number of subjects: 175
Study 16258098 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus G-CSF
Number of subjects: 175
Study 16258098 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 175
Study 12011969 — intervention group
Group type: EXPERIMENTAL
Intervention: HR 500 mg tid (Group A)
Number of subjects: 90
Study 12011969 — intervention group
Group type: EXPERIMENTAL
Intervention: HR 1 g tid (Group B)
Number of subjects: 90
Study 12011969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 90
Study 12011969 — intervention group
Group type: EXPERIMENTAL
Intervention: HR 1 g/day (Group D)
Number of subjects: 90
Study 10438378 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine/didanosine/hydroxyurea
Number of subjects: 18
Study 10438378 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine/didanosine
Number of subjects: 18
Study 8292945 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ties
Number of subjects: 15
Study 8292945 — intervention group
Group type: COMPARATOR
Intervention: Bow ties
Number of subjects: 15
Study 3318623 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow mercuric oxide 1% bid (41 patients)
Number of subjects: 78
Study 3318623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (37 patients)
Number of subjects: 78
Study 29861066 — intervention group
Group type: EXPERIMENTAL
Intervention: XP‐endo Shaper
Number of subjects: 0
Study 29861066 — intervention group
Group type: COMPARATOR
Intervention: Reciproc
Number of subjects: 0
Study 27084825 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg, 110 mg twice daily for 4 days)
Number of subjects: 91
Study 27084825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 24670356 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 genotypes
Number of subjects: 30
Study 24670356 — intervention group
Group type: EXPERIMENTAL
Intervention: CC/CT+TT (wild type GSTP1 exon 6)
Number of subjects: 30
Study 24670356 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 mutant genotype of exon 5 (GG), GSTP1 mutant and heterozygous genotypes of exon 6 (TT and CT)
Number of subjects: 30
Study 24670356 — intervention group
Group type: EXPERIMENTAL
Intervention: Null GSTM1, null GSTT1 and joint GSTM1/GSTT1 null genotypes
Number of subjects: 30
Study 24670356 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GST
Number of subjects: 30
Study 22517057 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Number of subjects: 88
Study 22517057 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 88
Study 21626817 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotropil, 400 mg/day for 1 year
Number of subjects: 400
Study 21626817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenotropil)
Number of subjects: 400
Study 16931161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program (CRP) - 8 weeks, hospital-based supervised exercise training (3 times per week, average intensity of 65% VO(2peak)) and individual education sessions.
Number of subjects: 60
Study 16931161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program (CRP) - 8 weeks, hospital-based supervised exercise training.
Number of subjects: 60